Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

BACKGROUND: In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the first trimester of pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenital malfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Shan-Yan, Wu, Qi-Jun, Sun, Ce, Zhang, Tie-Ning, Shen, Zi-Qi, Liu, Cai-Xia, Gong, Ting-Ting, Xu, Xin, Ji, Chao, Huang, Dong-Hui, Chang, Qing, Zhao, Yu-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231277/
https://www.ncbi.nlm.nih.gov/pubmed/30415641
http://dx.doi.org/10.1186/s12916-018-1193-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231277/
https://www.ncbi.nlm.nih.gov/pubmed/30415641
http://dx.doi.org/10.1186/s12916-018-1193-5

Ejemplares similares